OLD National Bancorp IN decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 100,310 shares of the medical research company’s stock after selling 7,212 shares during the quarter. OLD National Bancorp IN’s holdings in Edwards Lifesciences Corporation were worth $10,965,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. ETF Managers Group LLC bought a new stake in shares of Edwards Lifesciences Corporation during the 2nd quarter valued at $112,000. Shine Investment Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences Corporation during the 2nd quarter valued at $126,000. Cornerstone Advisors Inc. raised its position in shares of Edwards Lifesciences Corporation by 25.1% during the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 219 shares during the last quarter. Alexandria Capital LLC raised its position in shares of Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 19 shares during the last quarter. Finally, MPS Loria Financial Planners LLC bought a new stake in shares of Edwards Lifesciences Corporation during the 2nd quarter valued at $140,000. 82.37% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $115.99, for a total transaction of $3,816,071.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $112.15, for a total transaction of $594,395.00. The disclosure for this sale can be found here. Insiders have sold 196,480 shares of company stock worth $21,755,915 in the last quarter. Company insiders own 2.13% of the company’s stock.
Edwards Lifesciences Corporation (EW) traded up 0.54% during trading on Tuesday, reaching $102.18. The company’s stock had a trading volume of 538,870 shares. The company has a market cap of $21.58 billion, a P/E ratio of 30.99 and a beta of 0.62. The stock’s 50-day moving average is $110.17 and its 200 day moving average is $112.73. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.45.
Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The company had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same quarter in the prior year, the company posted $0.68 EPS. Edwards Lifesciences Corporation’s revenue for the quarter was up 11.1% on a year-over-year basis. On average, equities analysts forecast that Edwards Lifesciences Corporation will post $3.75 EPS for the current fiscal year.
Several analysts have commented on EW shares. Royal Bank Of Canada reiterated a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and set a $130.00 target price (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 target price for the company in a research report on Tuesday, July 18th. SunTrust Banks, Inc. upped their target price on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research report on Monday, July 17th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $135.00 target price (down previously from $155.00) on shares of Edwards Lifesciences Corporation in a research report on Wednesday, October 25th. Seven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $125.17.
Edwards Lifesciences Corporation Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.